Calcific aortic valve stenosis: Methods, models, and mechanisms

Circulation Research

Volumn 108, Issue 11, 2011, Pages 1392-1412

  Miller, Jordan D ^a   Weiss, Robert M ^b   Heistad, Donald D ^b,c  

^a MAYO CLINIC   (United States)

^b Department of Internal Medicine ^*  (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

animal models; calcification; echocardiography; fibrosis; phenotyping

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTILIPEMIC AGENT; APOLIPOPROTEIN E; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; CATHEPSIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; INTERLEUKIN 1; INTERSTITIAL COLLAGENASE; NITRIC OXIDE; NOTCH RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STROMELYSIN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE STENOSIS; ARTICLE; BONE DEVELOPMENT; CALCIFIC AORTIC VALVE STENOSIS; CALCIFICATION; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IN VIVO STUDY; LASER DOPPLER FLOWMETRY; LIPID STORAGE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST; OSTEOCLAST; OUTCOME ASSESSMENT; OXIDATIVE STRESS; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SMOKING; WESTERN BLOTTING;

AGING; ANIMALS; AORTIC VALVE STENOSIS; CALCINOSIS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; HUMANS;

EID: 79958147911     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.234138     Document Type: Article

References (239)

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011. (Pubitemid 44353666)
2. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS. 2008 focused update incorporated into the acc/aha 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118:e523-e661.
3. Beckmann E, Grau JB, Sainger R, Poggio P, Ferrari G. Insights into the use of biomarkers in calcific aortic valve disease. J Heart Valve Dis. 2010;19:441-452.
4. Messika-Zeitoun D, Bielak LF, Peyser PA, Sheedy PF, Turner ST, Nkomo VT, Breen JF, Maalouf J, Scott C, Tajik AJ, Enriquez-Sarano M. Aortic valve calcification: determinants and progression in the population. Arterioscler Thromb Vasc Biol. 2007;27:642-648.
5. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005; 111:3316-3326. (Pubitemid 40875006)
6. Qian J, Chen Z, Ge J, Ma J, Chang S, Fan B, Liu X, Ge L. Relationship between aortic valve calcification and the severity of coronary atherosclerotic disease. J Heart Valve Dis. 2010;19:466-470.
7. Mazzone A, Venneri L, Berti S. Aortic valve stenosis and coronary artery disease: pathophysiological and clinical links. J Cardiovasc Med (Hagerstown). 2007;8:983-989. (Pubitemid 351339554)
8. Heistad DD. Oxidative stress and vascular disease: 2005 Duff lecture. Arterioscler Thromb Vasc Biol. 2006;26:689-695. (Pubitemid 43732139)
9. Shao JS, Cheng SL, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension. 2010;55:579-592.
10. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol. 2010;7:528-536.
11. Barrick CJ, Roberts RB, Rojas M, Rajamannan NM, Suitt CB, O'Brien KD, Smyth SS, Threadgill DW. Reduced egfr causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in c57bl/6j but not 129s1/svimj mice. Am J Physiol Heart Circ Physiol. 2009;297:H65-H75.
12. Miller JD, Weiss RM, Serrano KM, Brooks RM, II, Berry CJ, Zimmerman K, Young SG, Heistad DD. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation. 2009;119: 2693-2701.
13. Miller JD, Weiss RM, Serrano KM, Castaneda LE, Brooks RM, Zimmerman K, Heistad DD. Evidence for active regulation of proosteogenic signaling in advanced aortic valve disease. Arterioscler Thromb Vasc Biol. 2010;30:2482-2486.
14. Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006;114: 2065-2069. (Pubitemid 44706883)
15. Tanaka K, Sata M, Fukuda D, Suematsu Y, Motomura N, Takamoto S, Hirata Y, Nagai R. Age-associated aortic stenosis in apolipoprotein e-deficient mice. J Am Coll Cardiol. 2005;46:134-141. (Pubitemid 40905141)
16. Drolet MC, Roussel E, Deshaies Y, Couet J, Arsenault M. A high fat/high carbohydrate diet induces aortic valve disease in c57bl/6j mice. J Am Coll Cardiol. 2006;47:850-855. (Pubitemid 43243111)
17. Hinton RB Jr, Alfieri CM, Witt SA, Glascock BJ, Khoury PR, Benson DW, Yutzey KE. Mouse heart valve structure and function: echocardiographic and morphometric analyses from the fetus through the aged adult. Am J Physiol Heart Circ Physiol. 2008;294:H2480-H2488.
18. Kupfahl C, Honold M, Meinhardt G, Vogelsberg H, Wagner A, Mahrholdt H, Sechtem U. Evaluation of aortic stenosis by cardiovascular magnetic resonance imaging: comparison with established routine clinical techniques. Heart. 2004;90:893-901. (Pubitemid 39005936)
19. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007;115:377-386. (Pubitemid 46148512)
20. Berry CJ, Miller JD, McGroary K, Thedens DR, Young SG, Heistad DD, Weiss RM. Biventricular adaptation to volume overload in mice with aortic regurgitation. J Cardiovasc Magn Reson. 2009;11:27.
21. Berry CJ, Thedens DR, Light-McGroary K, Miller JD, Kutschke W, Zimmerman KA, Weiss RM. Effects of deep sedation or general anesthesia on cardiac function in mice undergoing cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009;11:16.
22. Hanada K, Vermeij M, Garinis GA, de Waard MC, Kunen MG, Myers L, Maas A, Duncker DJ, Meijers C, Dietz HC, Kanaar R, Essers J. Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ Res. 2007;100:738-746. (Pubitemid 46594889)
23. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007;116:2841-2850. (Pubitemid 350301146)
24. Mehrabian M, Demer LL, Lusis AJ. Differential accumulation of intimal monocyte-macrophages relative to lipoproteins and lipofuscin corresponds to hemodynamic forces on cardiac valves in mice. Arterioscler Thromb. 1991;11:947-957.
25. Ovchinnikova O, Gylfe A, Bailey L, Nordstrom A, Rudling M, Jung C, Bergstrom S, Waldenstrom A, Hansson GK, Nordstrom P. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of apoe-deficient mice-brief report. Arterioscler Thromb Vasc Biol. 2009;29:1478-1480.
26. Ovchinnikova O, Robertson AK, Wagsater D, Folco EJ, Hyry M, Myllyharju J, Eriksson P, Libby P, Hansson GK. T-cell activation leads to reduced collagen maturation in atherosclerotic plaques of apoe(-/-) mice. Am J Pathol. 2009;174:693-700.
27. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol. 1994;89:397-410.
28. Burke AP, Kolodgie FD, Virmani R. Fetuin-a, valve calcification, and diabetes: what do we understand? Circulation. 2007;115:2464-2467.
29. Matsumoto Y, Adams V, Jacob S, Mangner N, Schuler G, Linke A. Regular exercise training prevents aortic valve disease in low-density lipoprotein-receptor-deficient mice. Circulation. 2010;121:759-767.
30. Chakraborty S, Wirrig EE, Hinton RB, Merrill WH, Spicer DB, Yutzey KE. Twist1 promotes heart valve cell proliferation and extracellular matrix gene expression during development in vivo and is expressed in human diseased aortic valves. Dev Biol. 2010;347:167-179.
31. Alfieri CM, Cheek J, Chakraborty S, Yutzey KE. Wnt signaling in heart valve development and osteogenic gene induction. Dev Biol. 2010;338: 127-135.
32. Miller AA, Drummond GR, De Silva TM, Mast AE, Hickey H, Williams JP, Broughton BR, Sobey CG. Nadph oxidase activity is higher in cerebral versus systemic arteries of four animal species: Role of nox2. Am J Physiol Heart Circ Physiol. 2009;296:H220-H225.
33. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, Fukuda D, Kohler RH, Shi GP, Jaffer FA, Weissleder R. Arterial and aortic valve calcification abolished by elastolytic cathepsin s deficiency in chronic renal disease. Circulation. 2009;119:1785-1794.
34. Hjortnaes J, Butcher J, Figueiredo JL, Riccio M, Kohler RH, Kozloff KM, Weissleder R, Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31:1975-1984.
35. Boyce R, Dorph-Petersen KA, Lyck L, Gundersen H. Design-based stereology: introduction to basic concepts and practical approaches for estimation of cell number. Toxicol Pathol. 2010;38:1011-1025.
36. Thomsen JS, Laib A, Koller B, Prohaska S, Mosekilde L, Gowin W. Stereological measures of trabecular bone structure: comparison of 3d micro computed tomography with 2d histological sections in human proximal tibial bone biopsies. J Microsc. 2005;218:171-179. (Pubitemid 40646647)
37. van Elburg HJ, Kuypers LC, Decraemer WF, Dirckx JJ. Improved correction of axial geometrical distortion in index-mismatched fluorescent confocal microscopic images using high-aperture objective lenses. J Microsc. 2007;228:45-54. (Pubitemid 47512255)
38. Kuypers LC, Decraemer WF, Dirckx JJ, Timmermans JP. A procedure to determine the correct thickness of an object with confocal microscopy in case of refractive index mismatch. J Microsc. 2005;218:68-78. (Pubitemid 40524170)
39. Briley-Saebo KC, Cho YS, Shaw PX, Ryu SK, Mani V, Dickson S, Izadmehr E, Green S, Fayad ZA, Tsimikas S. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J Am Coll Cardiol. 2011;57:337-347.
40. Chang K, Francis SA, Aikawa E, Figueiredo JL, Kohler RH, McCarthy JR, Weissleder R, Plutzky J, Jaffer FA. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol. 2010;30:1933-1939.
41. Jarrett BR, Correa C, Ma KL, Louie AY. In vivo mapping of vascular inflammation using multimodal imaging. PLoS One. 2010;5:e13254.
42. Hamilton AM, Rogers KA, Belisle AJ, Ronald JA, Rutt BK, Weissleder R, Boughner DR. Early identification of aortic valve sclerosis using iron oxide enhanced MRI. J Magn Reson Imaging. 2010;31:110-116.
43. Wirrig EE, Hinton RB, Yutzey KE. Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. J Mol Cell Cardiol. 2011;50:561-569.
44. Sucosky P, Balachandran K, Elhammali A, Jo H, Yoganathan AP. Altered shear stress stimulates upregulation of endothelial vcam-1 and icam-1 in a bmp-4-and tgf-beta1-dependent pathway. Arterioscler Thromb Vasc Biol. 2009;29:254-260.
45. Ni CW, Qiu H, Rezvan A, Kwon K, Nam D, Son DJ, Visvader JE, Jo H. Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow. Blood. 2010;116: e66-e73.
46. Csiszar A, Labinskyy N, Jo H, Ballabh P, Ungvari Z. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. Am J Physiol Heart Circ Physiol. 2008;295:H569-H577.
47. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, Fairchild-Huntress V, Dixon KL, Dunmore JH, Gimbrone MA Jr, Falb D, Huszar D. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet. 2000;24:171-174. (Pubitemid 30094719)
48. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707-1712.
49. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the lrp5 receptor pathway. Circulation. 2005;112: I229-I234. (Pubitemid 41266679)
50. Benton JA, Kern HB, Anseth KS. Substrate properties influence calcification in valvular interstitial cell culture. J Heart Valve Dis. 2008;17: 689-699.
51. Kennedy JA, Hua X, Mishra K, Murphy GA, Rosenkranz AC, Horowitz JD. Inhibition of calcifying nodule formation in cultured porcine aortic valve cells by nitric oxide donors. Eur J Pharmacol. 2009;602:28-35.
52. Clark-Greuel JN, Connolly JM, Sorichillo E, Narula NR, Rapoport HS, Mohler ER III, Gorman JH III, Gorman RC, Levy RJ. Transforming growth factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. Ann Thorac Surg. 2007;83: 946-953. (Pubitemid 46328821)
53. Cushing MC, Liao JT, Anseth KS. Activation of valvular interstitial cells is mediated by transforming growth factor-beta1 interactions with matrix molecules. Matrix Biol. 2005;24:428-437. (Pubitemid 41781640)
54. Walker GA, Masters KS, Shah DN, Anseth KS, Leinwand LA. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res. 2004;95:253-260. (Pubitemid 39056285)
55. Jian B, Narula N, Li QY, Mohler ER III, Levy RJ. Progression of aortic valve stenosis: Tgf-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003;75:457-465. (Pubitemid 36184488)
56. Mohler ER III, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis. 1999;8:254-260. (Pubitemid 29274326)
57. Chen JH, Chen WL, Sider KL, Yip CY, Simmons CA. {beta}-catenin mediates mechanically regulated, transforming growth factor-{beta}1-induced myofibroblast differentiation of aortic valve interstitial cells. Arterioscler Thromb Vasc Biol. 2011;31:590-597.
58. Yip CY, Chen JH, Zhao R, Simmons CA. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler Thromb Vasc Biol. 2009;29:936-942.
59. Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, Marshall GW, Marshall SJ, Ritchie RO, Derynck R, Alliston T. Tgf-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci USA. 2005;102:18813-18818. (Pubitemid 43049527)
60. Rajamannan NM. Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol. 2009;29: 162-168.
61. Wylie-Sears J, Aikawa E, Levine RA, Yang JH, Bischoff J. Mitral valve endothelial cells with osteogenic differentiation potential. Arterioscler Thromb Vasc Biol. 2011;31:598-607.
62. Paranya G, Vineberg S, Dvorin E, Kaushal S, Roth SJ, Rabkin E, Schoen FJ, Bischoff J. Aortic valve endothelial cells undergo transforming growth factor-beta-mediated and non-transforming growth factor-beta-mediated transdifferentiation in vitro. Am J Pathol. 2001; 159:1335-1343. (Pubitemid 32947963)
63. Eghbali-Fatourechi GZ, Modder UI, Charatcharoenwitthaya N, Sanyal A, Undale AH, Clowes JA, Tarara JE, Khosla S. Characterization of circulating osteoblast lineage cells in humans. Bone. 2007;40: 1370-1377. (Pubitemid 46550982)
64. Khosla S, Eghbali-Fatourechi GZ. Circulating cells with osteogenic potential. Ann N Y Acad Sci. 2006;1068:489-497. (Pubitemid 43824177)
65. Eghbali-Fatourechi GZ, Lamsam J, Fraser D, Nagel D, Riggs BL, Khosla S. Circulating osteoblast-lineage cells in humans. N Engl J Med. 2005;352:1959-1966. (Pubitemid 40638366)
66. Olmsted-Davis EA, Gugala Z, Camargo F, Gannon FH, Jackson K, Kienstra KA, Shine HD, Lindsey RW, Hirschi KK, Goodell MA, Brenner MK, Davis AR. Primitive adult hematopoietic stem cells can function as osteoblast precursors. Proc Natl Acad Sci USA. 2003;100: 15877-15882. (Pubitemid 38021083)
67. Visconti RP, Ebihara Y, LaRue AC, Fleming PA, McQuinn TC, Masuya M, Minamiguchi H, Markwald RR, Ogawa M, Drake CJ. An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ Res. 2006;98:690-696.
68. Heistad DD, Wakisaka Y, Miller J, Chu Y, Pena-Silva R. Novel aspects of oxidative stress in cardiovascular diseases. Circ J. 2009;73:201-207.
69. Rivera J, Sobey CG, Walduck AK, Drummond GR. Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. Redox Rep. 2010;15:50-63.
70. Gielis JF, Lin JY, Wingler K, Van Schil PE, Schmidt HH, Moens AL. Pathogenetic role of enos-uncoupling in cardiopulmonary disorders. Free Radic Biol Med. 2010.
71. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res. 2011;34:5-14.
72. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93:621-635.
73. Lassegue B, Griendling KK. Nadph oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol. 2010;30:653-661.
74. Leopold JA, Loscalzo J. Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med. 2009;47:1673-1706.
75. Essex DW. Redox control of platelet function. Antioxid Redox Signal. 2009;11:1191-1225.
76. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008;5:338-349. (Pubitemid 351761708)
77. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482-2494.
78. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Pena-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol. 2008;52:843-850.
79. Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J Jr, Pomerantzeff PM, Laurindo FR. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol. 2008;28:463-470.
80. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D. Nad(p)h oxidase 4 mediates transforming growth factorbeta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005;97:900-907. (Pubitemid 41552675)
81. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor runx2 by akt signaling. J Biol Chem. 2008;283:15319-15327.
82. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. 2001;31:509-519. (Pubitemid 32728438)
83. Guerraty MA, Grant GR, Karanian JW, Chiesa OA, Pritchard WF, Davies PF. Hypercholesterolemia induces side-specific phenotypic changes and peroxisome proliferator-activated receptor-gamma pathway activation in swine aortic valve endothelium. Arterioscler Thromb Vasc Biol. 2010;30:225-231.
84. Soini Y, Salo T, Satta J. Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum Pathol. 2003;34:756-763. (Pubitemid 37040610)
85. Charest A, Pepin A, Shetty R, Cote C, Voisine P, Dagenais F, Pibarot P, Mathieu P. Distribution of sparc during neovascularisation of degenerative aortic stenosis. Heart. 2006;92:1844-1849. (Pubitemid 44851338)
86. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoe-deficient mice. J Clin Invest. 2002; 110:331-340. (Pubitemid 34847965)
87. Cagirci G, Cay S, Canga A, Karakurt O, Yazihan N, Kilic H, Topaloglu S, Aras D, Demir AD, Akdemir R. Association between plasma asymmetrical dimethylarginine activity and severity of aortic valve stenosis. J Cardiovasc Med (Hagerstown). 2011;12:96-101.
88. Ngo DT, Heresztyn T, Mishra K, Marwick TH, Horowitz JD. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (adma). Nitric Oxide. 2007;16:197-201. (Pubitemid 46149393)
89. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart. 2005;91: 806-810. (Pubitemid 40769233)
90. Schmidt TS, McNeill E, Douglas G, Crabtree MJ, Hale AB, Khoo J, O'Neill CA, Cheng A, Channon KM, Alp NJ. Tetrahydrobiopterin supplementation reduces atherosclerosis and vascular inflammation in apolipoprotein e-knockout mice. Clin Sci (Lond). 2010;119:131-142.
91. Jensky NE, Criqui MH, Wright MC, Wassel CL, Brody SA, Allison MA. Blood pressure and vascular calcification. Hypertension. 2010;55: 990-997.
92. Kitazono T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD. Evidence that angiotensin ii is present in human monocytes. Circulation. 1995;91:1129-1134.
93. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin ii. Circulation. 1998;98:800-807. (Pubitemid 28391846)
94. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90: 844-853. (Pubitemid 24242754)
95. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J, Turto H, Kupari M, Kovanen PT. Induction of local angiotensin ii-producing systems in stenotic aortic valves. J Am Coll Cardiol. 2004;44:1859-1866. (Pubitemid 39424087)
96. Didion SP, Kinzenbaw DA, Schrader LI, Chu Y, Faraci FM. Endogenous interleukin-10 inhibits angiotensin ii-induced vascular dysfunction. Hypertension. 2009;54:619-624.
97. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. Il-6 deficiency protects against angiotensin ii induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol. 2007;27: 2576-2581. (Pubitemid 350158908)
98. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008;29: 367-374.
99. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T, Hanafusa T. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol. 2007;49:1482-1489. (Pubitemid 46482919)
100. Yamamoto K, Yamamoto H, Yoshida K, Kisanuki A, Hirano Y, Ohte N, Akasaka T, Takeuchi M, Nakatani S, Ohtani T, Sozu T, Masuyama T. Prognostic factors for progression of early-and late-stage calcific aortic valve disease in Japanese: the Japanese aortic stenosis study (JASS) retrospective analysis. Hypertens Res. 2010;33:269-274.
101. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensinconverting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004;110:1291-1295. (Pubitemid 39202347)
102. O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, Wu AH, Zhao XQ, Budoff MJ. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med. 2005; 165:858-862. (Pubitemid 40563231)
103. D'Amelio P, Isaia G, Isaia GC. The osteoprotegerin/rank/rankl system: a bone key to vascular disease. J Endocrinol Invest. 2009;32:6-9.
104. Boyce BF, Xing L. Biology of rank, rankl, and osteoprotegerin. Arthritis Res Ther. 2007;9(Suppl 1):S1.
105. Byon CH, Sun Y, Chen J, Yuan K, Mao X, Heath JM, Anderson PG, Tintut Y, Demer LL, Wang D, Chen Y. Runx2-upregulated receptor activator of nuclear factor {kappa}b ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol. 2011; PMID-21454810.
106. Sasaki H, Yamamoto H, Tominaga K, Masuda K, Kawai T, Teshima-Kondo S, Matsuno K, Yabe-Nishimura C, Rokutan K. Receptor activator of nuclear factor-kappab ligand-induced mouse oste-oclast differentiation is associated with switching between nadph oxidase homologues. Free Radic Biol Med. 2009;47:189-199.
107. Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS, Kim N, Lee SY. A crucial role for reactive oxygen species in rankl-induced osteoclast differentiation. Blood. 2005;106:852-859. (Pubitemid 41076424)
108. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S, Coll B, Fernandez E, Valdivielso JM. Rankl increases vascular smooth muscle cell calcification through a rank-bmp4-dependent pathway. Circ Res. 2009;104:1041-1048.
109. Orita Y, Yamamoto H, Kohno N, Sugihara M, Honda H, Kawamata S, Mito S, Soe NN, Yoshizumi M. Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler Thromb Vasc Biol. 2007;27:2058-2064. (Pubitemid 47312318)
110. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older apoe-/- mice. Arterioscler Thromb Vasc Biol. 2006; 26:2117-2124. (Pubitemid 44253797)
111. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation. 2008; 117:411-420.
112. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, Kilic R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagl S, Dempfle CE, Borggrefe M. Receptor activator of nuclear factor kappab ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004;36:57-66. (Pubitemid 38084791)
113. Steinmetz M, Skowasch D, Wernert N, Welsch U, Preusse CJ, Welz A, Nickenig G, Bauriedel G. Differential profile of the opg/rankl/ranksystem in degenerative aortic native and bioprosthetic valves. J Heart Valve Dis. 2008;17:187-193.
114. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res. 2008; 102:283-294. (Pubitemid 351271648)
115. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. Ppars and the cardiovascular system. Antioxid Redox Signal. 2009;11:1415-1452.
116. Kawaguchi H, Akune T, Yamaguchi M, Ohba S, Ogata N, Chung UI, Kubota N, Terauchi Y, Kadowaki T, Nakamura K. Distinct effects of ppargamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab. 2005;23:275-279. (Pubitemid 40875085)
117. Yamashita A, Takada T, Nemoto K, Yamamoto G, Torii R. Transient suppression of ppargamma directed es cells into an osteoblastic lineage. FEBS Lett. 2006;580:4121-4125. (Pubitemid 44037579)
118. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82. (Pubitemid 28079218)
119. Keen HL, Ryan MJ, Beyer A, Mathur S, Scheetz TE, Gackle BD, Faraci FM, Casavant TL, Sigmund CD. Gene expression profiling of potential ppargamma target genes in mouse aorta. Physiol Genomics. 2004;18: 33-42. (Pubitemid 39319484)
120. Yao Y, Watson AD, Ji S, Bostrom KI. Heat shock protein 70 enhances vascular bone morphogenetic protein-4 signaling by binding matrix gla protein. Circ Res. 2009;105:575-584.
121. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in esrd. J Am Soc Nephrol. 2004;15:2857-2867. (Pubitemid 41103395)
122. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix gla protein. Nature. 1997;386:78-81. (Pubitemid 27130923)
123. Yao Y, Bennett BJ, Wang X, Rosenfeld ME, Giachelli C, Lusis AJ, Bostrom KI. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 2010;107:485-494.
124. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in notch1 cause aortic valve disease. Nature. 2005;437:270-274. (Pubitemid 41294491)
125. Nigam V, Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol. 2009;47:828-834.
126. Luna-Zurita L, Prados B, Grego-Bessa J, Luxan G, del Monte G, Benguria A, Adams RH, Perez-Pomares JM, de la Pompa JL. Integration of a notch-dependent mesenchymal gene program and bmp2-driven cell invasiveness regulates murine cardiac valve formation. J Clin Invest. 2010;120:3493-3507.
127. Ann EJ, Kim HY, Choi YH, Kim MY, Mo JS, Jung J, Yoon JH, Kim SM, Moon JS, Seo MS, Hong JA, Jang WG, Shore P, Komori T, Koh JT, Park HS. Inhibition of notch1 signaling by runx2 during osteoblast differentiation. J Bone Miner Res. 2010.
128. Shimizu T, Tanaka T, Iso T, Doi H, Sato H, Kawai-Kowase K, Arai M, Kurabayashi M. Notch signaling induces osteogenic differentiation and mineralization of vascular smooth muscle cells: role of msx2 gene induction via notch-rbp-jk signaling. Arterioscler Thromb Vasc Biol. 2009;29:1104-1111.
129. Kaden JJ, Dempfle CE, Grobholz R, Fischer CS, Vocke DC, Kilic R, Sarikoc A, Pinol R, Hagl S, Lang S, Brueckmann M, Borggrefe M. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol. 2005;14:80-87. (Pubitemid 40381303)
130. Kaden JJ, Dempfle CE, Grobholz R, Tran HT, Kilic R, Sarikoc A, Brueckmann M, Vahl C, Hagl S, Haase KK, Borggrefe M. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis. 2003;170:205-211. (Pubitemid 37377791)
131. Jian B, Jones PL, Li Q, Mohler ER III, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-c in calcific aortic stenosis. Am J Pathol. 2001;159:321-327. (Pubitemid 33704217)
132. Kaden JJ, Vocke DC, Fischer CS, Grobholz R, Brueckmann M, Vahl CF, Hagl S, Haase KK, Dempfle CE, Borggrefe M. Expression and activity of matrix metalloproteinase-2 in calcific aortic stenosis. Z Kardiol. 2004;93:124-130. (Pubitemid 38241503)
133. Edep ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol. 2000;9: 281-286.
134. Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M, Hvass U, Couetil JP, Henin D, Michel JB, Vahanian A, Jacob MP. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J. 2005;26:1333-1341. (Pubitemid 41435466)
135. Helske S, Syvaranta S, Lindstedt KA, Lappalainen J, Oorni K, Mayranpaa MI, Lommi J, Turto H, Werkkala K, Kupari M, Kovanen PT. Increased expression of elastolytic cathepsins s, k, and v and their inhibitor cystatin c in stenotic aortic valves. Arterioscler Thromb Vasc Biol. 2006;26:1791-1798. (Pubitemid 44313582)
136. Helske S, Syvaranta S, Kupari M, Lappalainen J, Laine M, Lommi J, Turto H, Mayranpaa M, Werkkala K, Kovanen PT, Lindstedt KA. Possible role for mast cell-derived cathepsin g in the adverse remodelling of stenotic aortic valves. Eur Heart J. 2006;27:1495-1504. (Pubitemid 43998085)
137. Pacifici R, Carano A, Santoro SA, Rifas L, Jeffrey JJ, Malone JD, McCracken R, Avioli LV. Bone matrix constituents stimulate interleukin-1 release
138. Qin X, Corriere MA, Matrisian LM, Guzman RJ. Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol. 2006;26:1510-1516. (Pubitemid 44288976)
139. Isoda K, Matsuki T, Kondo H, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in balb/c mice. Arterioscler Thromb Vasc Biol. 2010;30:708-715.
140. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA. Aortic msx2-wnt calcification cascade is regulated by tnf-alpha-dependent signals in diabetic ldlr-/- mice. Arterioscler Thromb Vasc Biol. 2007;27:2589-2596. (Pubitemid 350158910)
141. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappab and inflammatory activation. Circulation. 2009;119:1386-1397.
142. Cecil DL, Terkeltaub RA. Arterial calcification is driven by rage in enpp1-/- mice. J Vasc Res. 2010;48:227-235.
143. Ren X, Shao H, Wei Q, Sun Z, Liu N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res. 2009;37:847-854.
144. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through rage/p38 mapk. J Vasc Res. 2009;46:572-580.
145. Towler DA. Vascular calcification: it's all the rage! Arterioscler Thromb Vasc Biol. 2011;31:237-239.
146. Hofmann Bowman MA, Gawdzik J, Bukhari U, Husain AN, Toth PT, Kim G, Earley J, McNally EM. S100a12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein e-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol. 2011;31:337-344.
147. Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA. Vascular remodeling and arterial calcification are directly mediated by s100a12 (en-rage) in chronic kidney disease. Am J Nephrol. 2011;33: 250-259.
148. Katz R, Budoff MJ, Takasu J, Shavelle DM, Bertoni A, Blumenthal RS, Ouyang P, Wong ND, O'Brien KD. Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: the multi-ethnic study of atherosclerosis (mesa). Diabetes. 2009;58: 813-819.
149. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13:1971-1978.
150. Basta G, Corciu AI, Vianello A, Del Turco S, Foffa I, Navarra T, Chiappino D, Berti S, Mazzone A. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis. 2010;210:614-618.
151. Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001;103:1522-1528. (Pubitemid 32226259)
152. Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab. 2004;286: E686-E696. (Pubitemid 38506938)
153. Kalantari F, Miao D, Emadali A, Tzimas GN, Goltzman D, Vali H, Chevet E, Auguste P. Cellular and molecular mechanisms of abnormal calcification following ischemia-reperfusion injury in human liver transplantation. Mod Pathol. 2007;20:357-366. (Pubitemid 46348335)
154. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA. 2004; 101:4477-4482. (Pubitemid 38437436)
155. Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev CI, Sebo TJ, Rosengart TK, Edwards WD, McCarthy PM, Bonow RO, Spelsberg TC. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation. 2005;111:3296-3301. (Pubitemid 40875003)
156. Yperman J, De Visscher G, Holvoet P, Flameng W. Molecular and functional characterization of ovine cardiac valve-derived interstitial cells in primary isolates and cultures. Tissue Eng. 2004;10:1368-1375. (Pubitemid 39557841)
157. Stephens EH, Saltarrelli JG, Baggett LS, Nandi I, Kuo JJ, Davis AR, Olmsted-Davis EA, Reardon MJ, Morrisett JD, Grande-Allen KJ. Differential proteoglycan and hyaluronan distribution in calcified aortic valves. Cardiovasc Pathol. 2011; PMID-21185747; PMCID-PMC3075347.
158. Gupta V, Werdenberg JA, Blevins TL, Grande-Allen KJ. Synthesis of glycosaminoglycans in differently loaded regions of collagen gels seeded with valvular interstitial cells. Tissue Eng. 2007;13:41-49. (Pubitemid 46178380)
159. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006;126:677-689. (Pubitemid 44233625)
160. Monzack EL, Gu X, Masters KS. Efficacy of simvastatin treatment of valvular interstitial cells varies with the extracellular environment. Arterioscler Thromb Vasc Biol. 2009;29:246-253.
161. Rodriguez KJ, Masters KS. Regulation of valvular interstitial cell calcification by components of the extracellular matrix. J Biomed Mater Res A. 2009;90:1043-1053.
162. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE, Daemen MJ. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol. 2002;22:975-982. (Pubitemid 34655226)
163. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165-197.
164. Demer LL, Tintut Y. Mechanisms linking osteoporosis with cardiovascular calcification. Curr Osteoporos Rep. 2009;7:42-46.
165. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. J Am Coll Cardiol. 1997;29:630-634. (Pubitemid 27116107)
166. Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, Erdos MR, Blair C, Funke B, Smoot L, Gerhard-Herman M, Machan JT, Kutys R, Virmani R, Collins FS, Wight TN, Nabel EG, Gordon LB. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol. 2010;30: 2301-2309.
167. Nair K, Ramachandran P, Krishnamoorthy KM, Dora S, Achuthan TJ. Hutchinson-Gilford progeria syndrome with severe calcific aortic valve stenosis and calcific mitral valve. J Heart Valve Dis. 2004;13:866-869.
168. Makous N, Friedman S, Yakovac W, Maris EP. Cardiovascular manifestations in progeria. Report of clinical and pathologic findings in a patient with severe arteriosclerotic heart disease and aortic stenosis. Am Heart J. 1962;64:334-346.
169. Sogawa M, Kasuya S, Yamamoto K, Koshika M, Oguma F, Hayashi J. Aortic valve replacement for aortic stenosis with a small aortic annulus in a patient having Werner's syndrome and liver cirrhosis. Ann Thorac Cardiovasc Surg. 2001;7:378-380.
170. Grubitzsch H, Beholz S, Wollert HG, Eckel L. Severe heart valve calcification in a young patient with werner syndrome. Cardiovasc Pathol. 2000;9:53-54. (Pubitemid 30157878)
171. Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, Shroff R, Skepper J, Shanahan CM. Prelamin a acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation. 2010;121:2200-2210.
172. Capell BC, Olive M, Erdos MR, Cao K, Faddah DA, Tavarez UL, Conneely KN, Qu X, San H, Ganesh SK, Chen X, Avallone H, Kolodgie FD, Virmani R, Nabel EG, Collins FS. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci USA. 2008;105: 15902-15907.
173. Masuda H, Chikuda H, Suga T, Kawaguchi H, Kuro-o M. Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice. Mech Ageing Dev. 2005;126:1274-1283. (Pubitemid 41572244)
174. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51. (Pubitemid 27494749)
175. Small EM, Frost RJ, Olson EN. Micrornas add a new dimension to cardiovascular disease. Circulation. 2010;121:1022-1032.
176. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian micrornas predominantly act to decrease target mrna levels. Nature. 2010;466: 835-840.
177. Chen LH, Chiou GY, Chen YW, Li HY, Chiou SH. Microrna and aging: a novel modulator in regulating the aging network. Ageing Res Rev. 2010;9(Suppl 1):S59-S66.
178. Nigam V, Sievers HH, Jensen BC, Sier HA, Simpson PC, Srivastava D, Mohamed SA. Altered micrornas in bicuspid aortic valve: a comparison between stenotic and insufficient valves. J Heart Valve Dis. 2010;19: 459-465.
179. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of micrornas after myocardial infarction reveals a role of mir-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 2008;105:13027-13032.
180. Schroeder TM, Kahler RA, Li X, Westendorf JJ. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem. 2004;279:41998-42007. (Pubitemid 39313651)
181. Stein S, Schafer N, Breitenstein A, Besler C, Winnik S, Lohmann C, Heinrich K, Brokopp CE, Handschin C, Landmesser U, Tanner FC, Luscher TF, Matter CM. Sirt1 reduces endothelial activation without affecting vascular function in apoe-/- mice. Aging (Albany NY). 2010; 2:353-360.
182. Schwer B, Schumacher B, Lombard DB, Xiao C, Kurtev MV, Gao J, Schneider JI, Chai H, Bronson RT, Tsai LH, Deng CX, Alt FW. Neural sirtuin 6 (sirt6) ablation attenuates somatic growth and causes obesity. Proc Natl Acad Sci USA. 2010;107:21790-21794.
183. Burgess RJ, Zhang Z. Roles for gcn5 in promoting nucleosome assembly and maintaining genome integrity. Cell Cycle. 2010;9: 2979-2985.
184. De Carvalho DD, You JS, Jones PA. DNA methylation and cellular reprogramming. Trends Cell Biol. 2010;20:609-617.
185. Montes de Oca A, Madueno JA, Martinez-Moreno JM, Guerrero F, Munoz-Castaneda J, Rodriguez-Ortiz ME, Mendoza FJ, Almaden Y, Lopez I, Rodriguez M, Aguilera-Tejero E. High-phosphate-induced calcification is related to sm22alpha promoter methylation in vascular smooth muscle cells. J Bone Miner Res. 2010;25:1996-2005.
186. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F, Rajamannan NM. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554-561. (Pubitemid 46177435)
187. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
188. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397. (Pubitemid 40958435)
189. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (astronomer) trial. Circulation. 2010;121:306-314.
190. Rikitake Y, Liao JK. Rho gtpases, statins, and nitric oxide. Circ Res. 2005;97:1232-1235.
191. Zhou Q, Liao JK. Pleiotropic effects of statins- basic research and clinical perspectives. Circ J. 2010;74:818-826.
192. Makris GC, Lavida A, Nicolaides AN, Geroulakos G. The effect of statins on carotid plaque morphology: a ldl-associated action or one more pleiotropic effect of statins? Atherosclerosis. 2010;213:8-20.
193. Stary HC. The development of calcium deposits in atherosclerotic lesions and their persistence after lipid regression. Am J Cardiol. 2001; 88:16E-19E. (Pubitemid 32721978)
194. Stary HC. Natural history of calcium deposits in atherosclerosis progression and regression. Z Kardiol. 2000;89(Suppl 2):28-35.
195. Cappelli S, Epistolato MC, Vianello A, Mazzone A, Glauber M, Franzini M, Ottaviano V, Pompella A, Paolicchi A, Tanganelli P. Aortic valve disease and gamma-glutamyltransferase: accumulation in tissue and relationships with calcific degeneration. Atherosclerosis. 2010;213: 385-391.
196. Shuvy M, Ben Ya'acov A, Zolotarov L, Lotan C, Ilan Y. Beta glycosphingolipids suppress rank expression and inhibit natural killer t cell and cd8- accumulation in alleviating aortic valve calcification. Int J Immunopathol Pharmacol. 2009;22:911-918.
197. Satta J, Melkko J, Pollanen R, Tuukkanen J, Paakko P, Ohtonen P, Mennander A, Soini Y. Progression of human aortic valve stenosis is associated with tenascin-c expression. J Am Coll Cardiol. 2002;39: 96-101. (Pubitemid 34059867)
198. Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ, Detrano RC, Dunstan CR, Shah PK, Rajavashisth TB. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA. 2003;100:11201-11206. (Pubitemid 37205912)
199. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2003;23:489-494. (Pubitemid 36337227)
200. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation. 1994;89:1810-1818. (Pubitemid 24114261)
201. Gomez D, Coyet A, Ollivier V, Jeunemaitre X, Jondeau G, Michel JB, Vranckx R. Epigenetic control of vascular smooth muscle cellsin marfan and non-marfan thoracic aorticaneurysms. Cardiovasc Res. 2011;89: 446-456.
202. Webber J, Meran S, Steadman R, Phillips A. Hyaluronan orchestrates transforming growth factor-beta1-dependent maintenance of myofibroblast phenotype. J Biol Chem. 2009;284:9083-9092.
203. Gerdts E, Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the seas study). Am J Cardiol. 2010;106: 1634-1639.
204. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol. 2008;101:14D-19D.
205. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res. 2010;107:106-116.
206. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the at2 receptor comes of age. Hypertension. 2005;45: 840-844. (Pubitemid 40628923)
207. Ferrario CM. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin i metabolism. Hypertension. 2010;55:445-452.
208. Hu C, Dandapat A, Chen J, Liu Y, Hermonat PL, Carey RM, Mehta JL. Over-expression of angiotensin ii type 2 receptor (agtr2) reduces atherogenesis and modulates lox-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis. 2008;199:288-294.
209. Zeng W, Chen W, Leng X, He JG, Ma H. Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the tgf-beta/smad signaling pathway in rabbits. Biochem Biophys Res Commun. 2009;389:138-144.
210. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by pparalpha, beta/delta, and gamma. J Clin Invest. 2004;114:1564-1576. (Pubitemid 40385547)
211. Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation. 2007;116:2182-2190. (Pubitemid 350060356)
212. van Rooij E. The art of microrna research. Circ Res. 2011;108:219-234.
213. Quiles JL, Mesa MD, Ramirez-Tortosa CL, Aguilera CM, Battino M, Gil A, Ramirez-Tortosa MC. Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arterioscler Thromb Vasc Biol. 2002;22:1225-1231. (Pubitemid 34764878)
214. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181-2184. (Pubitemid 36547209)
215. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95: 592-600.
216. Bilik D, McEwen LN, Brown MB, Pomeroy NE, Kim C, Asao K, Crosson JC, Duru OK, Ferrara A, Hsiao VC, Karter AJ, Lee PG, Marrero DG, Selby JV, Subramanian U, Herman WH. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab. 2010;95:4560-4565.
217. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (adopt). Diabetes Care. 2008;31: 845-851.
218. Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L, Goellner J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. Foxo-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010;11: 136-146.
219. Salmon AB, Richardson A, Perez VI. Update on the oxidative stress theory of aging: does oxidative stress play a role in aging or healthy aging? Free Radic Biol Med. 2010;48:642-655.
220. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319. (Pubitemid 27199902)
221. Leibbrandt A, Penninger JM. Rank(l) as a key target for controlling bone loss. Adv Exp Med Biol. 2009;647:130-145.
222. Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, Koriyama H, Shimamura M, Miyake T, Rakugi H, Morishita R. Estrogen inhibits vascular calcification via vascular rankl system: common mechanism of osteoporosis and vascular calcification. Circ Res. 2010;107:466-475.
223. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptordeficient mice. J Biol Chem. 2003;278:50195-50202. (Pubitemid 37548859)
224. Lee TC, Zhao YD, Courtman DW, Stewart DJ. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation. 2000;101:2345-2348. (Pubitemid 30329122)
225. Tkatchenko TV, Moreno-Rodriguez RA, Conway SJ, Molkentin JD, Markwald RR, Tkatchenko AV. Lack of periostin leads to suppression of notch1 signaling and calcific aortic valve disease. Physiol Genomics. 2009;39:160-168.
226. Hakuno D, Kimura N, Yoshioka M, Mukai M, Kimura T, Okada Y, Yozu R, Shukunami C, Hiraki Y, Kudo A, Ogawa S, Fukuda K. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and mmp production in humans and rodents. J Clin Invest. 2010;120:2292-2306.
227. Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Kimura N, Shukunami C, Okada Y, Mukai M, Shin H, Yozu R, Sata M, Ogawa S, Hiraki Y, Fukuda K. Chondromodulin-i maintains cardiac valvular function by preventing angiogenesis. Nat Med. 2006;12:1151-1159. (Pubitemid 44527350)
228. Cimini M, Boughner DR, Ronald JA, Aldington L, Rogers KA. Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study. J Heart Valve Dis. 2005; 14:365-375. (Pubitemid 47050751)
229. Cuniberti LA, Stutzbach PG, Guevara E, Yannarelli GG, Laguens RP, Favaloro RR. Development of mild aortic valve stenosis in a rabbit model of hypertension. J Am Coll Cardiol. 2006;47:2303-2309. (Pubitemid 43795060)
230. Drolet MC, Couet J, Arsenault M. Development of aortic valve sclerosis or stenosis in rabbits: role of cholesterol and calcium. J Heart Valve Dis. 2008;17:381-387.
231. Gkizas S, Koumoundourou D, Sirinian X, Rokidi S, Mavrilas D, Koutsoukos P, Papalois A, Apostolakis E, Alexopoulos D, Papadaki H. Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis. Eur J Pharmacol. 2010;642: 107-112.
232. Hekimian G, Passefort S, Louedec L, Houard X, Jacob MP, Vahanian A, Michel JB, Messika-Zeitoun D. High-cholesterol- vitamin d2 regimen: a questionable in-vivo experimental model of aortic valve stenosis. J Heart Valve Dis. 2009;18:152-158.
233. Marechaux S, Corseaux D, Vincentelli A, Richardson M, Ung A, Susen S, Zawadzki C, Beregi JP, Ezekowitz MD, Jude B, Le Tourneau T. Identification of tissue factor in experimental aortic valve sclerosis. Cardiovasc Pathol. 2009;18:67-76.
234. Ngo DT, Stafford I, Kelly DJ, Sverdlov AL, Wuttke RD, Weedon H, Nightingale AK, Rosenkranz AC, Smith MD, Chirkov YY, Kennedy JA, Horowitz JD. Vitamin d(2) supplementation induces the development of aortic stenosis in rabbits: interactions with endothelial function and thioredoxin-interacting protein. Eur J Pharmacol. 2008;590:290-296.
235. Ngo DT, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y, Kelly DJ, Weedon H, Smith MD, Kennedy JA, Horowitz JD. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br J Pharmacol. 2011;162:722-732.
236. Rajamannan NM, Sangiorgi G, Springett M, Arnold K, Mohacsi T, Spagnoli LG, Edwards WD, Tajik AJ, Schwartz RS. Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis. 2001;10:371-374. (Pubitemid 32454760)
237. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002; 105:2660-2665. (Pubitemid 34596044)
238. Speidl WS, Cimmino G, Ibanez B, Elmariah S, Hutter R, Garcia MJ, Fuster V, Goldman ME, Badimon JJ. Recombinant apolipoprotein a-i milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur Heart J. 2010;31: 2049-2057.
239. Simmons CA, Grant GR, Manduchi E, Davies PF. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res. 2005;96:792-799. (Pubitemid 40559519)